Journal article
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
- Abstract:
-
Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn’s disease (CD) naïve to immunosuppressants and biologics using a UK public payer perspective.
Design A regression model estimated weekly CD Activity Index (CDAI)-based transition matrices (remission: CDAI <150, moderate: CDAI ≥150 to <300,...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group Publisher's website
- Journal:
- Gut Journal website
- Volume:
- 69
- Issue:
- 4
- Pages:
- 658-664
- Publication date:
- 2019-07-08
- Acceptance date:
- 2019-06-12
- DOI:
- EISSN:
-
1468-3288
- ISSN:
-
0017-5749
- Pmid:
-
31285357
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:1033058
- UUID:
-
uuid:03ab2042-b70f-4e25-8240-bfc35e965c52
- Local pid:
- pubs:1033058
- Source identifiers:
-
1033058
- Deposit date:
- 2019-07-20
Terms of use
- Copyright holder:
- Panaccione et al.
- Copyright date:
- 2019
- Rights statement:
- © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record